^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
472P - Whole genome sequencing of metastatic CRC reveals footprints from the past and present with future clinical relevance
Published date:
09/14/2020
Excerpt:
In addition to KRAS/NRAS and BRAF, mutations in FBXW7 were associated with poor response to EGFR-targeted treatments.
Trial ID:
Source:
Title:
Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type “window of opportunity”
Published date:
10/09/2018
Excerpt:
CONTRADICTING EVIDENCE: 15 mCRC patients harboring any RAS mutation in tumor tissue....5 of them have received EGFR inhibitors as a second-line treatment, achieving a durable clinical benefit.
DOI:
10.1093/annonc/mdy281.095
Source:
Title:
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
Excerpt:
We retrospectively collected the clinical data of KRAS exon 2 wild type (WT) mCRC patients treated with EGFR inhibitor monotherapy or EGFR inhibitor plus irinotecan as third-line chemotherapy. The association between primary tumor location, RAS (KRAS exon 3, 4 or NRAS), BRAF V600E, and PIK3CA mutational status, and treatment outcome was evaluated….In multivariate analysis, RAS (p=0.004) and BRAF mutations (p=0.00008) were independent factors for shorter PFS. Poor performance status (p=0.01) and BRAF mutation (p=0.00002) were independent factors for shorter OS...
Secondary therapy:
irinotecan
DOI:
10.21873/anticanres.15186
Source:
Title:
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
Excerpt:
We retrospectively collected the clinical data of KRAS exon 2 wild type (WT) mCRC patients treated with EGFR inhibitor monotherapy or EGFR inhibitor plus irinotecan as third-line chemotherapy. The association between primary tumor location, RAS (KRAS exon 3, 4 or NRAS), BRAF V600E, and PIK3CA mutational status, and treatment outcome was evaluated….In multivariate analysis, RAS (p=0.004) and BRAF mutations (p=0.00008) were independent factors for shorter PFS. Poor performance status (p=0.01) and BRAF mutation (p=0.00002) were independent factors for shorter OS...
DOI:
10.21873/anticanres.15186
